सभी अध्ययन
सक्रिय लेकिन भर्ती नहींचरण 2हस्तक्षेपात्मक

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

The AGLOW study is a research project focusing on a new medicine, VX-407, for adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD). This condition causes fluid-filled sacs (cysts) to grow in the kidneys, which can lead to kidney damage over time. The main goal of this study is to find out if VX-407 can slow down the growth of these cysts by measuring changes in kidney size. Researchers will also be checking if the medicine is safe to use, if people can tolerate it well, and how the body processes it. This early-stage study is an important step in understanding if VX-407 could be a future treatment option for ADPKD, specifically for patients with certain genetic features.

एक नजर में

स्थिति
सक्रिय लेकिन भर्ती नहीं
चरण
चरण 2
प्रायोजक
वर्टेक्स फार्मास्यूटिकल्स इनकॉर्पोरेटेड
नामांकन लक्ष्य
26
प्रारंभ
19 Nov 2025
अनुमानित पूर्णता
31 दिसम्बर 2027

यह अध्ययन किस बारे में है?

This study, named AGLOW, is investigating a new medication called VX-407 for people living with Autosomal Dominant Polycystic Kidney Disease (ADPKD). ADPKD is a genetic condition where fluid-filled sacs, known as cysts, develop and multiply in the kidneys. Over time, these cysts can enlarge the kidneys and reduce their ability to function properly, potentially leading to kidney failure.

The main aim of this research is to see how VX-407 affects the size of the kidneys, as increased kidney size is often a sign of ADPKD progressing. Researchers will be measuring your kidney volume (adjusted for your height) to see if the medicine can slow down cyst growth. They also want to understand if VX-407 is safe for patients to use, if it causes any side effects, and how the body absorbs, distributes, and removes the medicine (what scientists call 'pharmacokinetics').

This is an early-stage study (Phase 2a), which means it's one of the first times this specific medicine is being tested in a larger group of patients to assess its effectiveness and safety. The insights gained from AGLOW will be crucial in deciding if VX-407 has the potential to become a treatment for ADPKD, particularly for individuals who have specific genetic changes in their PKD1 gene.

मुख्य निष्कर्ष

  • This study is testing a new medicine (VX-407) for ADPKD.
  • It aims to see if the medicine can slow down kidney cyst growth.
  • Participation requires regular hospital visits and health monitoring.
  • You must be 18-65 years old and have a specific type of ADPKD.
  • Potential benefits and risks will be fully explained before you decide to join.
  • आप किसी भी समय अध्ययन से हट सकते हैं।.

कौन पात्र हो सकता है?

To join this study, you must have been diagnosed with Autosomal Dominant Polycystic Kidney Disease (ADPKD) and be willing to attend all scheduled appointments and follow the study instructions. Your kidney cysts would also need to meet certain measurements seen on a special MRI scan (Mayo imaging classification 1B with a kidney size of at least 250 mL/m, 1C, 1D, or 1E).

Your kidneys also need to be working at a certain level. Specifically, your estimated kidney function (eGFR) must be 25 millilitres per minute per 1.73 square metre or higher. You must be between 18 and 65 years old, and the study is open to both men and women.

There are also some reasons why you wouldn't be able to join. For example, if you have another kidney condition not related to ADPKD, or if you've had a kidney or other organ transplant, or if you've had a kidney removed. People who are currently on dialysis or expect to start dialysis within the next year would also not be able to participate. The study team will review all your medical information to make sure it's safe and appropriate for you to join.

क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?

यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.

  1. Do you have a diagnosis of ADPKD?
  2. क्या आपकी उम्र 18 से 65 वर्ष के बीच है?
  3. क्या आप नियमित रूप से क्लिनिक विज़िट पर जा सकते हैं?
  4. Has an MRI scan shown your kidney condition meets certain criteria (like Mayo 1B with a specific size, 1C, 1D, or 1E)?
  5. Is your kidney function (eGFR) at least 25 mL/min/1.73 m² or higher?
  6. Have you not had a kidney transplant or other major organ transplant?
अपने परिणाम देखने के लिए हर प्रश्न का उत्तर दें।.

भागीदारी में क्या शामिल है?

If you decide to take part in the AGLOW study, you will have regular visits to the clinic so the research team can monitor your health and the effects of the study medicine. These visits will involve various tests and assessments, including blood and urine samples, and possibly repeat MRI scans to measure your kidney size. You will be taking the study medicine, VX-407, as directed by the study team. You will also have follow-up appointments after you stop taking the medicine to ensure your health is still being monitored. The total duration of your involvement in the study will be explained in detail by the research team.

संभावित जोखिम और लाभ

Taking part in any clinical study carries potential benefits and risks. For this study, a potential benefit could be that VX-407 might help slow down the progression of your ADPKD, although this is not guaranteed as it's a new medicine being tested. It's also possible you may not experience any direct benefits. Potential risks could include side effects from the medication or discomfort from study procedures like blood tests or MRI scans. The research team will explain all known or expected risks in detail. Remember, participation is completely voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

स्थान (43)

  • Alabama Kidney Research
    सत्यापित पोस्टकोड
    Alabaster, United States
  • UAB Nephrology Research at CH19
    सत्यापित पोस्टकोड
    बर्मिंघम, संयुक्त राज्य अमेरिका
  • Kaiser Permanente Los Angeles Medical Center
    सत्यापित पोस्टकोड
    लॉस एंजेलेस, संयुक्त राज्य अमेरिका
  • UCSF Clinical Research Center at Parnassus
    सत्यापित पोस्टकोड
    सैन फ्रांसिस्को, संयुक्त राज्य अमेरिका
  • Nephrology & Hypertension Associates, PC
    सत्यापित पोस्टकोड
    Middlebury, United States
  • Yale University - Yale Nephrology Clinical Research Clinic
    सत्यापित पोस्टकोड
    न्यू हेवन, संयुक्त राज्य अमेरिका
  • Mayo Clinic - Jacksonville
    सत्यापित पोस्टकोड
    जैक्सनविल, संयुक्त राज्य अमेरिका
  • Emory School of Medicine - Renal Division
    सत्यापित पोस्टकोड
    अटलांटा, संयुक्त राज्य अमेरिका
  • Renal Associates
    सत्यापित पोस्टकोड
    कोलंबस, संयुक्त राज्य अमेरिका
  • UChicago Medicine - Duchossois Center for Advanced Medicine - Nephrology
    सत्यापित पोस्टकोड
    शिकागो, संयुक्त राज्य अमेरिका
  • University of Iowa Health Care Medical Center- Nephrology
    सत्यापित पोस्टकोड
    आयोवा सिटी, संयुक्त राज्य अमेरिका
  • Clinical & Translational Science Unit (CTSU) - Nephrology
    सत्यापित पोस्टकोड
    कैनसस सिटी, संयुक्त राज्य अमेरिका

सामान्य प्रश्न

What is ADPKD?

ADPKD stands for Autosomal Dominant Polycystic Kidney Disease. It's a genetic condition where fluid-filled sacs called cysts grow in your kidneys, which can affect their function over time.

What is VX-407?

VX-407 is a new medicine being studied. This research project is trying to find out if it's safe and effective for treating ADPKD.

क्या मुझे निश्चित रूप से नई दवा मिलेगी?

In some studies, participants are randomly assigned to receive the study medicine or a placebo (a dummy medicine). The researchers will explain exactly what this means for you.

क्या मुझे इस अध्ययन में शामिल होने के लिए भुगतान करना होगा?

No, you will not have to pay to participate in the study, and study-related medical care and the study medicine will be provided free of charge. Travel expenses may also be reimbursed.

अगर मैं भाग लेने के बारे में अपना मन बदल लूँ तो क्या होगा?

You have the right to leave the study at any time, for any reason, without having to explain why. Your decision will not affect your ongoing medical care.

और अधिक जानने के लिए कैसे पता करें

किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.

चर्चा

समुदाय चर्चा

हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.